Restoring tissue health and rejuvenating lives
Protein signaling dysregulation leads to degenerative diseases
Juvena maps the therapeutic potential of natural secreted proteins and engineers them into biologics that restore tissue homeostasis
Secreted proteins are released by cells to direct cellular repair, promote tissue regeneration, and drive healthy communication between different body systems. As our bodies age or as a result of genetic mutations, protein signaling can become dysregulated leading to a loss of tissue homeostasis. The resulting tissue degeneration manifests as a loss of healthy bodily functions and onset of chronic diseases.
Juvena’s platform mines thousands of proteins secreted by human stem cells, screens their potential to restore tissue homeostasis, and engineers novel biologic medicines into life-saving treatments.
Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases.
Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases.
We are achieving this through a fully integrated, end-to-end artificial intelligence-enabled platform that combines a diverse protein library, in silico mapping of secreted proteins to specific disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering capabilities.
AI-powered analysis drives rapid expansion of our protein candidate library, hit generation and target validation
In vivo validation of protein bioactivity enables optimization of clinical impact and safety
Advanced protein engineering synthesizes novel biologics
Juvena has developed new tools to overcome translational barriers and pioneer treatments like our first-in-class myotonic dystrophy program. We partnered with the Myotonic Dystrophy Foundation to deliver transformative outcomes for patients.
Myotonic Dystrophy Type 1 is a genetic disorder causing progressive muscle degeneration and metabolic impairments. It impacts skeletal muscle and frequently disrupts cardiac conduction, respiration, swallowing, and cognitive function.
Additional metabolic diseases Juvena focuses on include obesity, sarcopenia, lung and liver diseases.
Learn about our flagship lead biologic asset and our other programs utilizing the power of secreted proteins to make an unprecedented impact against unhealthy aging and diseases.
Juvena has developed new tools to overcome translational barriers and pioneer treatments like our first-in-class myotonic dystrophy program. We partnered with the Myotonic Dystrophy Foundation to deliver transformative outcomes for patients.
Myotonic Dystrophy Type 1 is a genetic disorder causing progressive muscle degeneration and metabolic impairments. It impacts skeletal muscle and frequently disrupts cardiac conduction, respiration, swallowing, and cognitive function.
Additional metabolic diseases Juvena focuses on include obesity, sarcopenia, lung and liver diseases.
Learn about our flagship lead biologic asset and our other programs utilizing the power of secreted proteins to make an unprecedented impact against unhealthy aging and diseases.
We are leveraging an AI-enabled platform to systematically map the therapeutic potential of secreted proteins and engineer them into novel therapeutics. Learn more about our growing pipeline.
We are always looking to advance research with synergistic partnerships. Contact us today to learn more about partnering or investing with us.
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
Juvena is selected by the World Economic Forum to join its 2024 global cohort of Technology Pioneers, awarded to the 100 most innovative tech startups applying new breakthroughs in AI to solve some of the biggest challenges of our time
Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences
CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare
The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging
640 Galveston Drive
Redwood City, CA 94063
Get Directions »
650.223.5879
info@juvenatherapeutics.com
© 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy